Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07289477 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jul 2027 to Oct 2027 · Start date changed from estimate of Dec 2025 to Jan 5, 2026 · Site details revisedv2 Show 3 more changesShow less
    • Primary completion date: Jul 2027 to Oct 2027
    • Start date changed from estimate of Dec 2025 to Jan 5, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
Trial Details
NCT Number NCT07289477
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov